Table 1 Baseline demographics.

From: The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study

  

Pre-COVID

n = 486

COVID

n = 501

p-value

Median age, years (IQR)

 

73 (66–81)

73 (65–80)

0.665

Age quintile, years

<60

70 (14.4%)

71 (14.1%)

0.705

 

60–70

122 (25.2%)

134 (26.7%)

 

71–75

88 (18.2%)

83 (16.5%)

 

76–80

77 (15.9%)

96 (19.1%)

 

>80

126 (26%)

117 (23.3%)

Gender

Male

258 (53.4%)

268 (53.4%)

0.981

WHO/ECOG performance status

0

153 (31.6%)

165 (32.9%)

0.521a

 

1

137 (28.3%)

155 (30.9%)

 

2

101 (20.9%)

81 (16.1%)

 

>3

92 (19%)

100 (19.9%)

Country

England

381 (78.8%)

393 (78.4%)

0.241

 

Scotland

49 (10.1%)

38 (7.5%)

 

Wales

22 (4.5%)

34 (6.7%)

 

Northern Ireland

31 (6.4%)

36 (7.1%)

Index multiple deprivation quintileb

1

94 (20.6%)

95 (20%)

0.704a

 

2

82 (17.9%)

79 (16.6%)

 

3

111 (24.3%)

132 (27.7%)

 

4

100 (21.9%)

84 (17.6%)

 

5

69 (15.1%)

85 (17.8%)

Body mass indexc

Underweight

32 (7.1%)

44 (9.5%)

0.152a

 

Normal

263 (59.1%)

275 (59.7%)

 

Overweight

98 (22%)

96 (20.8%)

 

Moderately obese

38 (8.5%)

39 (8.4%)

 

Severely obese

9 (2%)

5 (1%)

 

Very severely obese

5 (1.1%)

1 (0.2%)

Charlson comorbidity index score

<5

353 (73.08%)

355 (70.85%)

0.429a

 

5–7

114 (23.6%)

127 (25.34%)

 

>7

16 (3.31%)

19 (3.79%)

Jaundiced

N (%)

186 (39%)

195 (39.7%)

0.839

Pathway intent

 Curative

N (%)

94 (19.5%)

77 (15.4%)

0.09

 Non-curative

N (%)

389 (80.5%)

424 (84.6%)

  1. Data are reported as median (IQR), with p-value from Mann–Whitney U-test, or as N (%), with p-value from chi-square test, unless stated otherwise.
  2. aOrdinal Data p-values from Mann–Whitney-U-test.
  3. bn = 456, 94.4% pre-COVID and n = 475, 94.8% COVID.
  4. cn = 445, 92.2% pre-COVID and n = 460, 91.8% COVID.